BioNTech SE - ADR
BNTX
Get informed when a big investor buys or sells
+ FollowEarnings Call Q4 2025
March 10, 2026 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
45.4% downsideOvervalued by 45.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $22.90 Billion |
|---|---|
| Enterprise Value | $14.01 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.51 |
| Beta | 1.32 |
| Outstanding Shares | 252,884,261 |
Return
| Return on Equity | -6.72% |
|---|---|
| Return on Assets | -5.96% |
| Return on Invested Capital | -6.91% |
Valuation & Multiples
| P/E Ratio | -15.76 |
|---|---|
| PEG | -52.49 |
| Price to Sales | 8.23 |
| Price to Book Ratio | 1.22 |
| Enterprise Value to Revenue | 5.01 |
| Enterprise Value to EBIT | -10.49 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.2657▲ 118.56% |
|---|---|
| Total Calls | 719,765▼ 38.80% |
| Total Puts | 1,630,805▲ 28.37% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 19.61%▼ 0.42% |
|---|---|
| Total Invested | $4.21B▼ 7.66% |
| Investors Holding | 300▼ 18.00% |
ESG Score
No data
About BioNTech SE
Relevant Senate Committees
Provides technical analysis and scoring for tax legislation; directly influences corporate tax structures and the overall tax burden for companies like BioNTech.
Controls taxation, trade, and entitlement spending (e.g., Medicare); directly impacts BioNTech's profitability through corporate tax policy and revenue streams through drug pricing and coverage decisions.
Allocates discretionary federal spending; directly impacts funding for health agencies (e.g., NIH, CDC, FDA) and the DoD, which procure BioNTech's products or fund related research.
Regulates the FDA and NIH; directly impacts BioNTech's product approval processes, research funding opportunities, and the overall regulatory environment for pharmaceuticals and biologics.
Oversees antitrust laws and intellectual property; directly impacts BioNTech's core business through patent protection, licensing, and potential merger/acquisition scrutiny.
Receives classified briefings on global threats; information related to biosecurity threats or pandemics could directly impact BioNTech's product development, government contracts, or emergency response efforts.